VEPTR Implantation to Treat Children With Early Onset Scoliosis Without Rib Abnormalities

NCT ID: NCT00689533

Last Updated: 2008-06-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-01-31

Study Completion Date

2016-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary Objective: To evaluate the use of unilateral or bilateral VEPTR devices, with or without expansion thoracoplasty, for preventing further progression of the Cobb angle, allowing for spinal growth and improving pulmonary function in the treatment of children with progressive scoliosis without rib abnormalities.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Number of Patients Planned: A total of 250 patients requiring treatment with the VEPTR device and meeting the inclusion/exclusion criteria will be enrolled in the study. All patients enrolled in this study will receive the VEPTR device.

Duration of Follow-up: Patients will be clinically followed post-surgery throughout the course of the patient's treatment. Follow-up appointments will be scheduled at 1, 6, and 12 months post-surgery and every year thereafter until 5 years after the index procedure, then every 2 years until the final planned procedure, or the completion or spinal growth (typically about 2 years after menarche in girls, or the equivalent in boys), whichever occurs first. Other patient visits may occur as deemed necessary.

General Design and Methodology: This is a prospective, multi-center, clinical study to evaluate the use of VEPTR devices for preventing further progression of the Cobb angle, a measure of the curvature of the spine, determined from measurements made on radiographs, allowing for spinal growth and improving pulmonary function in the treatment of children with progressive scoliosis without rib abnormalities. Unilateral vs. Bilateral, and use of an opening wedge thoracostomy, are at the discretion of the surgeon. The treatment would be used regardless of the study, therefore it is routine care. The primary study hypothesis is that, in regard to key clinical and radiographic outcomes, the success rate of the VEPTR device is at least 90%. A secondary study hypothesis is that in regards to key pulmonary outcomes (improvement in pulmonary function tests and increase in lung volume as measured by CT scans), the success rate of the VEPTR device is at least 90% (see Primary Study Endpoints below). Details of the patient outcomes and the study hypothesis are given below. With correction for 10% attrition, 250 patients split between the participating institutions will be enrolled.

Primary Study Endpoints: The primary endpoint will be based on the findings up to and including the last scheduled patient follow-up visit. An individual patient's treatment will be considered successful only if each of the following criteria are met:

* The patient's Cobb angle at the final surgery is less than or equal to the patient's pre-operative Cobb angle and
* The patient's trunk height or spinal length at final surgery is greater than or equal to the patient's immediate post-operative trunk height or spinal length

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Congenital Progressive Scoliosis Infantile

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

VEPTR TIS scoliosis juvenile

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Progressive scoliosis: idiopathic, congenital, syndromic, neuromuscular
* Progressive scoliosis with a Cobb angle that has advanced beyond 45˚
* 18 months to 10 years of age with open triradiate cartilages

Exclusion Criteria

* Presence of fused ribs
* Presence of multiple absent ribs
* Thoracic dysplasia such as Jeune's syndrome or equivalent condition
* Prior spinal fusion or spinal instrumentation
* Patient is participating in another clinical trial using investigational devices/drugs
* Patient is unable or unwilling to sign a consent form
Minimum Eligible Age

18 Months

Maximum Eligible Age

10 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chest Wall and Spine Deformity Research Foundation

OTHER

Sponsor Role collaborator

Shriners Hospitals for Children

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Chest Wall and Spine Deformity Study Group

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

John M Flynn, MD

Role: PRINCIPAL_INVESTIGATOR

Children's Hospital of Philadelphia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Site Status RECRUITING

Shriners Hospital for Children

Philadelphia, Pennsylvania, United States

Site Status NOT_YET_RECRUITING

Primary Children's Hospital

Salt Lake City, Utah, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sarah Mumford, MBA

Role: CONTACT

Phone: 801-662-5637

Email: [email protected]

Tricia St. Hilaire, BS

Role: CONTACT

Phone: 215-430-4147

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CWSD0003

Identifier Type: -

Identifier Source: org_study_id